Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + fluorouracil + trastuzumab
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy and targeted therapy regimen consisting of four drugs: - Cyclophosphamide (an alkylating agent) - Epirubicin (an anthracycline antibiotic) - Fluorouracil (5-FU; an antimetabolite/pyrimidine analog) - Trastuzumab (a monoclonal antibody targeting HER2) The regimen is primarily used for the treatment of HER2-positive breast cancer. Cyclophosphamide works by cross-linking DNA strands, leading to cell death. Epirubicin intercalates into DNA and inhibits topoisomerase II, preventing DNA replication. Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. Trastuzumab binds to the human epidermal growth factor receptor 2 (HER2), blocking its signaling and marking cells for immune destruction. This combination is typically administered in early-stage or locally advanced HER2-positive breast cancer as neoadjuvant or adjuvant therapy to reduce recurrence risk or shrink tumors before surgery[5][6][7]. The addition of trastuzumab specifically targets cancers overexpressing HER2 protein.
- Other names
- FEC-TFEC-THcyclophosphamide/epirubicin/fluorouracil/trastuzumab
02
Targets
DNAERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + fluorouracil + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + fluorouracil + trastuzumab.